Prodrugs may be inherently abuse-deterrent because they are inactive or significantly less active until conversion to the active drug. This requirement for conversion in the GI tract can modify the pharmacokinetic profile and eliminate or reduce the euphoria when abusers change the route of administration
Prodrugs are biologically inactive substances that are metabolized inside the body to their active form. Development of a prodrug that lacks opioid activity until it has been metabolized in the gastrointestinal (GI) tract may be an attractive option to prevent IV or intranasal routes of abuse.